mbiomics designs and develops complex microbiome-based therapeutics to change the treatment paradigm of severe and chronic diseases. They utilize proprietary precision analytics and patient insights to build a pipeline of rationally selected microbial communities, aiming to restore healthy microbial ecosystems and overcome disease. The company focuses on developing a new generation of complex live bacterial therapeutics (LBT) using a proprietary fluorescence microscopy-based profiling technology.